Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Steven Gill has been appointed to the newly created role of vice president of thought leader engagement at Alimera Sciences. Most recently, Gill was the associate director, thought leader liaison at Novartis U.S.
Stefanos Theoharis has been named chief business officer of Belgian biotech Bone Therapeutics. Previously, Theoharis served as senior vice president at Cell Medica.
BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics has announced the appointment of David Setboun to the role of executive vice president and chief operating officer. Setboun was most recently the vice president of corporate development of strategy and business at Life Biosciences.
Troy Player has been named president of early-stage development and testing at Cambrex. Player arrived at Cambrex after serving as vice president and general manager of the contract manufacturing business unit at West Pharmaceuticals.
ChroniSense Medical has tapped Bridget Ross to lead the company in the role of CEO. Previously, Ross was president of the global medical group at Henry Schein.
Lisa Ricciardi has stepped down from her previous position on the board of directors at Cognition Therapeutics to assume the position of acting CEO. The role was left vacant after Kenneth Moch stepped down to assume an advisory position.
Arthur DeCillis has joined Cybrexa Therapeutics as the company’s acting chief medical officer. DeCillis will continue serving as president of his own consulting company, DeCillis Consulting.
Carlos Campoy has been recruited by CytomX to assume the roles of senior vice president and chief financial officer. Campoy was most recently chief financial officer of Alder BioPharmaceuticals.
Cytovance has announced the promotion of Jesse McCool to CEO. Previously, McCool held the position of chief technology officer.
Gigi Feng has been selected to be I-Mab’s new vice president and global head of corporate communications. Feng was recently global communications head at Sanofi. Fernando Sallés has been appointed to the newly created role of senior vice president and head of U.S. and E.U. business development. Prior to this role, Sallés was a business development executive at Pteropsida Ventures.
Jonathan Rigby has been named CEO of clinical-stage biotech company Immune Regulation. Rigby was most recently president and CEO of SteadyMed Therapeutics.
Menlo Therapeutics has named Andrew Saik the organization’s chief financial officer and treasurer. Previously, Saik was chief financial officer of PDS Biotechnology.
Michael Wyzga has taken on the role of interim chief financial officer following the departure of Richard Jones. Wyzga previously held the positions of president and CEO of Radius Health.
Stephen Stamp, chief financial officer of Midatech Pharma, now holds the combined roles of CEO and chief financial officer, following the departure of prior CEO Craig Cook.
Gregory Stein has been named head of clinical development of Plus Therapeutics. Stein is co-founder and most recently CEO of Curtana Pharmaceuticals.
PRISYM ID has announced that Richard Adams will join the company as its CEO. Previously, Adams was the divisional director of healthcare at Wilmington. The company’s chief financial officer role will be assumed by Lauren Patterson, who was most recently chief financial officer at Revium Group.
William Macias has assumed the position of interim chief medical officer at Promethera Biosciences, immediately following Etienne Sokal’s transition from the role to become the company’s senior scientific and medical adviser.
Geoff Fatzinger has been appointed to the role of global head of regulatory affairs at Q BioMed. Fatzinger’s regulatory expertise spans 20 years across all phases of product development.
Recursion has tapped Michael Secora as its chief financial officer. Prior to taking this position, Secora was managing director and head of capital markets and venture of Laurion Capital.
Relmada Therapeutics has appointed Marc de Somer to the role of senior vice president of clinical development and safety. Most recently, de Somer was chief medical officer of Prilenia Therapeutics.
Hunter Smith, chief financial officer of Rhythm Pharmaceuticals, will now act as the company’s interim CEO.
Tatsuya Kaihara has been appointed to the role of corporate officer and head of North America business of Santen Pharmaceutical as well as CEO of its subsidiary Santen. Kaihara previously served as chief strategy officer and deputy chief executive and financial officer of Santen.
Seneca Biopharma has hired Matthew Kalnik to take on the roles of president and chief operating officer. Kalnik is the founder and previous CEO of Antidote Therapeutics. Dane Saglio has also been hired to the role of chief financial officer at Seneca. Most recently, Saglio was chief financial officer of RegeneRx Biopharmaceuticals. Seneca has promoted Thomas Hazel, who has held senior positions within the company for 17 years, to the role of senior vice president of research and development.
Maritza McIntyre has been named chief development officer of StrideBio. McIntyre was most recently the president of Advanced Therapy Partners.
Clinical-stage biopharmaceutical company Vaccibody has appointed Gunnstein Norheim, who most recently served as vaccine science director at CEPI, to lead the company’s infectious disease research and development strategy.
Vertex’s former chief medical officer, Reshma Kewalramani, has stepped into the CEO spot left open by Jeffrey Leiden’s move up to executive chairman. Kewalramani, who has a background in R&D, is only the second woman to head up a big pharma company, joining GSK’s Emma Walmsley.
Jerome Zeldis has joined ViralClear Pharmaceuticals, a new division of BioSig Technologies, as executive chair. Most recently, Zeldis was CEO of Celgene Global Health and chief medical officer of Celgene.